Pharmacogenetics Committee

Last Updated: Tuesday, 28 August 2018 15:11

	Chair Vincent Haufroid Brussels, Belgium	Contact Us Scientific Committees Pharmacogenetics Committee
	Vice-Chair Nicholas Picard Limoges, France

Background & Purpose of the Committee

• To promote the knowledge about clinically relevant DNA testing to optimize drug therapy
• To enhance the translation of research into clinical practice
• To encourage discussions on the clinical relevance of specific pharmacogenetics tests, to encourage research into clinically important areas with respect to drug treatment
• To encourage interaction between pharmacologist and toxicologist to promote “toxicogenetics”

Committee Initiatives for 2018/2019

• Make proposal for IATDMCT PGx session in Foz Do Iguassu, Brazil, 2019
• Propose/validate a (minimal) NGS panel to be used for pharmacogenetic applications in the field of TDM and CT (to be published in IATDMCT Compass)
• Explore the need for updated PGx guidelines in immunosuppressive therapy

Committee Initiatives Completed in 2016/2017

• Informed members of IATDMCT on current discussions regarding PGx testing, on new potentially interesting pharmacogenetic markers, and the emergence of new technologies.
• Represented IATDMCT in  IFCC, AACC, EFLM, IUPHAR and ESPT for initiatives on PGx.
• Advised IATDMCT Rotterdam committee on scientific program regarding PGx

Additional Committee Resources

Coming Soon!